Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.52 |
| ▸ | ANPEP | P15144 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481411 | 0.82 | KMT2A (0.47) | MMELPAR1POLBHTTNPSR1 | |
| SCHEMBL6476211 | 0.80 | HPGD (0.48) | MMELPAR1POLBHTTNPSR1 | |
| SCHEMBL6480017 | 0.79 | ANPEP (0.50) | MMEANPEPFOLH1 | |
| Acetylleucine SCHEMBL27388958 | 0.78 | ALDH1A1 (0.56) | MMEANPEPATMFOLH1LTA4H | |
| SCHEMBL6474692 | 0.78 | CYP2C9 (0.47) | MMEANPEPATMPOLBHTT | |
| Acetylleucine SCHEMBL27387792 | 0.76 | ALDH1A1 (0.58) | MMEANPEPATMFOLH1LPAR1 | |
| SCHEMBL7426384 | 0.75 | ANPEP (0.51) | MMEANPEPTDP1LTA4H | |
| SCHEMBL27996628 | 0.75 | KMT2A (0.55) | LPAR1POLBHTTNPSR1L3MBTL1 | |
| SCHEMBL7539990 | 0.74 | KMT2A (0.51) | ANPEPLPAR1POLBHTTNPSR1 | |
| SCHEMBL8653691 | 0.74 | MAPK1 (0.53) | MMEANPEPFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939888-B2 | 1-H-3-arylpirrolidine-2,4-dione derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-09-06 | — | — | US | disclosed |
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | FISCHER REINER (DE) | 2004-01-29 | — | — | US | disclosed |
| US-6472419-B1 | 1-H-3-aryl-pyrrolidine-2, 4-dione derivatives as pest-control agents | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019061-A1 | 1-H-3-arylpirrolidine-2,4-dione derivatives | PRXL2A, DDT, CYP4B1 | MME 3340/4885ANPEP 2333/4885TDP1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.